⚙
AI-generated deep summary
by claude@2026-06, 2026-06-07
· read from full text
ⓘ
This review examines novel pharmacological strategies for managing chronic pelvic pain in endometriosis by comparing the pharmacologic mechanisms, pharmacokinetics, and safety profiles of the progestin dienogest versus oral GnRH antagonists (elagolix, relugolix, linzagolix). Across included randomized and observational trials, it highlights differences in estrogen suppression, adverse events—especially bone mineral density loss and hypoestrogenic symptoms—and notes regulatory considerations. A stated caveat is that treatment selection depends on evidence spanning multiple study types and that emerging concepts like biomarkers and pain phenotyping are presented as potential tools rather than established decision metrics. This paper is centrally about endometriosis—specifically comparing dienogest with oral GnRH antagonists for chronic pelvic pain management and their safety/to-suppress-estrogen tradeoffs.
Abstract
INTRODUCTION: Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting about 10% of reproductive-age women. Chronic pelvic pain is its most disabling symptom, and available therapies often show limited long-term efficacy and tolerability. This review examines novel pharmacological strategies to improve outcomes.
AREAS COVERED: We compare the pharmacological, pharmacokinetic, and safety profiles of dienogest and oral GnRH antagonists (elagolix, relugolix, linzagolix). Mechanisms of action, levels of estrogen suppression, adverse events, particularly bone mineral density loss and hypoestrogenic symptoms, and regulatory aspects are discussed. Literature selection followed SANRA guidelines, with a comprehensive search of PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Library up to 2026. Eligible studies included randomized and observational trials reporting clinical or pharmacological outcomes. Emerging biomarkers such as progesterone receptor expression, epigenetic modifications, and pain phenotyping are also highlighted as potential tools for treatment personalization.
EXPERT OPINION: Dienogest and oral GnRH antagonists share anti-inflammatory and anti-proliferative effects but differ in pharmacodynamics and safety. Dienogest remains a well-tolerated long-term option in estrogen-sensitive patients, whereas GnRH antagonists are better suited for severe or refractory cases requiring rapid control. Integrating molecular and clinical profiling will be crucial to optimize individualized therapy and long-term outcomes.
Full text
2,849 characters
· extracted from
oa-doi-fallback
· click to expand
ABSTRACT
Introduction
Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting about 10% of reproductive-age women. Chronic pelvic pain is its most disabling symptom, and available therapies often show limited long-term efficacy and tolerability. This review examines novel pharmacological strategies to improve outcomes.
Areas covered
We compare the pharmacological, pharmacokinetic, and safety profiles of dienogest and oral GnRH antagonists (elagolix, relugolix, linzagolix). Mechanisms of action, levels of estrogen suppression, adverse events, particularly bone mineral density loss and hypoestrogenic symptoms, and regulatory aspects are discussed. Literature selection followed SANRA guidelines, with a comprehensive search of PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Library up to 2026. Eligible studies included randomized and observational trials reporting clinical or pharmacological outcomes. Emerging biomarkers such as progesterone receptor expression, epigenetic modifications, and pain phenotyping are also highlighted as potential tools for treatment personalization.
Expert opinion
Dienogest and oral GnRH antagonists share anti-inflammatory and anti-proliferative effects but differ in pharmacodynamics and safety. Dienogest remains a well-tolerated long-term option in estrogen-sensitive patients, whereas GnRH antagonists are better suited for severe or refractory cases requiring rapid control. Integrating molecular and clinical profiling will be crucial to optimize individualized therapy and long-term outcomes.
Article highlights
Dienogest and oral GnRH antagonists are key therapeutic options for endometriosis-associated pelvic pain, with distinct mechanisms and tolerability profiles.
Dienogest ensures long-term symptom relief with minimal hypoestrogenic side effects and preservation of bone mineral density.
Oral GnRH antagonists (elagolix, relugolix, linzagolix) provide rapid, reversible estrogen suppression with flexible dosing and add-back therapy options.
Emerging biomarkers, including progesterone receptor expression, epigenetic alterations, and pain phenotyping, may guide personalized treatment strategies.
Shared decision-making and precision medicine are crucial to optimize outcomes and avoid unnecessary exposure to ineffective or poorly tolerated therapies.
Declaration of interests
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.